Article info
PDFOriginal research
Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study
- Correspondence to Dr Eugenia Piscitelli, U.O.C. Farmacia, Ospedale Cardarelli, Napoli 80131, Italy; eugenia.piscitelli{at}aocardarelli.it
Citation
Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study
Publication history
- Received June 27, 2020
- Revised October 5, 2020
- Accepted October 7, 2020
- First published October 29, 2020.
Online issue publication
January 07, 2022
Article Versions
- Previous version (7 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.